Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

5/5/25 4:05:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MLYS alert in real time by email

RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025.

*Monday, May 12*^th @ 4:30 p.m. ET
Domestic:	1-800-717-1738
International:	1-646-307-1865
Conference ID:	53214
Webcast:	Link

A live webcast of the conference call may also be found on the "News & Events" page in the Investor Relations section of the Mineralys Therapeutics website.

About Mineralys Therapeutics

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.

Contact:

Investor Relations

[email protected]

Media Relations

Tom Weible

Elixir Health Public Relations

Phone: (1) 515-707-9678

Email: [email protected]

Get the next $MLYS alert in real time by email

Date

Price Target

Rating

Analyst

6/11/2025

$15.00

Hold

Jefferies

7/10/2024

$30.00

Buy

H.C. Wainwright

4/2/2024

$30.00

Buy

Goldman

3/7/2023

Outperform

Evercore ISI

3/7/2023

$39.00

Buy

BofA Securities

3/7/2023

$32.00

Buy

Guggenheim

3/7/2023

$27.00

Overweight

Wells Fargo

3/7/2023

$45.00

Buy

Stifel

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Chat with this insight

Recent Analyst Ratings for
$MLYS

$MLYS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

Large owner Samsara Biocapital Gp, Llc bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

Director Akkaraju Srinivas bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

$MLYS
SEC Filings

Mineralys Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form 144 filed by Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

$MLYS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Rodman David Malcom exercised 6,348 shares at a strike of $1.08 and sold $165,931 worth of shares (11,366 units at $14.60), decreasing direct ownership by 5% to 101,651 units (SEC Form 4)

Chief Medical Officer Rodman David Malcom sold $173,774 worth of shares (11,366 units at $15.29), decreasing direct ownership by 10% to 106,669 units (SEC Form 4)

Chief Medical Officer Rodman David Malcom exercised 6,349 shares at a strike of $1.08, increasing direct ownership by 6% to 118,035 units (SEC Form 4)

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Chat with this insight

Recent Analyst Ratings for $MLYS

$MLYS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

Large owner Samsara Biocapital Gp, Llc bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

Director Akkaraju Srinivas bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

$MLYS SEC Filings

Mineralys Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form 144 filed by Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

$MLYS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Rodman David Malcom exercised 6,348 shares at a strike of $1.08 and sold $165,931 worth of shares (11,366 units at $14.60), decreasing direct ownership by 5% to 101,651 units (SEC Form 4)

Chief Medical Officer Rodman David Malcom sold $173,774 worth of shares (11,366 units at $15.29), decreasing direct ownership by 10% to 106,669 units (SEC Form 4)

Chief Medical Officer Rodman David Malcom exercised 6,349 shares at a strike of $1.08, increasing direct ownership by 6% to 118,035 units (SEC Form 4)

Recent Analyst Ratings for
$MLYS

$MLYS
Insider Purchases

$MLYS
SEC Filings

$MLYS
Insider Trading